These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Striatal neurons express increased level of dopamine D2 receptor mRNA in response to haloperidol treatment: a quantitative in situ hybridization study. Bernard V; Le Moine C; Bloch B Neuroscience; 1991; 45(1):117-26. PubMed ID: 1754061 [TBL] [Abstract][Full Text] [Related]
23. Anatomical localization of SKF-38393-induced behaviors in rats using the irreversible monoamine receptor antagonist EEDQ. Neisewander JL; Ong A; McGonigle P Synapse; 1995 Feb; 19(2):134-43. PubMed ID: 7725242 [TBL] [Abstract][Full Text] [Related]
24. Effects of irreversible dopamine receptor inactivation on locomotor activity and grooming in the 17- and 90-day-old rat. McDougall SA; Crawford CA; Nonneman AJ Psychopharmacology (Berl); 1992; 106(4):502-10. PubMed ID: 1349753 [TBL] [Abstract][Full Text] [Related]
25. Effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on the prolactin suppression induced by a series of full and partial dopamine D2 receptor agonists in male rats. Ekman A; Eriksson E Naunyn Schmiedebergs Arch Pharmacol; 1992 Aug; 346(2):152-7. PubMed ID: 1360151 [TBL] [Abstract][Full Text] [Related]
26. Day/night differences in D1 but not D2 DA receptor protection from EEDQ denaturation in rats treated with continuous cocaine. Burger LY; Martin-Iverson MT Synapse; 1993 Jan; 13(1):20-9. PubMed ID: 8093985 [TBL] [Abstract][Full Text] [Related]
27. Evidence for dopamine D-2 receptors on cholinergic interneurons in the rat caudate-putamen. Dawson VL; Dawson TM; Filloux FM; Wamsley JK Life Sci; 1988; 42(20):1933-9. PubMed ID: 2966886 [TBL] [Abstract][Full Text] [Related]
29. Evidence for a fast receptor turnover of D1 dopamine receptors in various forebrain regions of the rat. Fuxe K; Agnati LF; Merlo Pich E; Meller E; Goldstein M Neurosci Lett; 1987 Oct; 81(1-2):183-7. PubMed ID: 3320818 [TBL] [Abstract][Full Text] [Related]
30. Effects of the two partial D2 agonists (+)- and (-)-3-PPP on prolactin release in EEDQ treated male rats. Ekman A; Quiding M; Eriksson E Life Sci; 1991; 48(4):311-20. PubMed ID: 1671291 [TBL] [Abstract][Full Text] [Related]
31. Brain receptor autoradiography with [3H]-YM 09151-2: a ligand for labeling dopamine D-2 receptors. Unis AS; Vincent JG; Dillon B Life Sci; 1990; 47(25):PL151-5. PubMed ID: 2148202 [TBL] [Abstract][Full Text] [Related]
32. Localized alterations of dopamine receptor binding in rat brain by repeated electroconvulsive shock: an autoradiographic study. Barkai AI; Durkin M; Nelson HD Brain Res; 1990 Oct; 529(1-2):208-13. PubMed ID: 2149297 [TBL] [Abstract][Full Text] [Related]
33. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Meller E; Bohmaker K; Namba Y; Friedhoff AJ; Goldstein M Mol Pharmacol; 1987 Jun; 31(6):592-8. PubMed ID: 2885734 [TBL] [Abstract][Full Text] [Related]
34. Effect of aging on recovery of striatal dopamine receptors following N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) blockade. Henry JM; Roth GS Life Sci; 1984 Aug; 35(8):899-904. PubMed ID: 6482680 [TBL] [Abstract][Full Text] [Related]
35. Effect of cocaine self-administration on dopamine D2 receptors in rhesus monkeys. Moore RJ; Vinsant SL; Nader MA; Porrino LJ; Friedman DP Synapse; 1998 Sep; 30(1):88-96. PubMed ID: 9704885 [TBL] [Abstract][Full Text] [Related]
36. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain. Xu SX; Hatada Y; Black LE; Creese I; Sibley DR J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530 [TBL] [Abstract][Full Text] [Related]
37. Heterogeneous distribution of dopamine D2 receptor mRNA in the rat striatum: a quantitative analysis with in situ hybridization histochemistry. Szele FG; Artymyshyn R; Molinoff PB; Chesselet MF Anat Rec; 1991 Dec; 231(4):548-58. PubMed ID: 1838906 [TBL] [Abstract][Full Text] [Related]
38. In vivo labeling of brain dopamine D2 receptors using the high-affinity specific D2 agonist [3H]CV 205-502. Closse A; Camps M; Wanner A; Palacios JM Brain Res; 1988 Feb; 440(1):123-32. PubMed ID: 2965955 [TBL] [Abstract][Full Text] [Related]
39. Regional variability in changes in 5-HT2A receptor mRNA levels in rat brain following irreversible inactivation with EEDQ. Raghupathi RK; Artymyshyn R; McGonigle P Brain Res Mol Brain Res; 1996 Jul; 39(1-2):198-206. PubMed ID: 8804728 [TBL] [Abstract][Full Text] [Related]
40. A high dose of EEDQ reduces pituitary dopamine D2 receptor density and the prolactin suppressive potency of agonists. Ekman A; Eriksson E Eur J Pharmacol; 1993 Oct; 243(3):295-9. PubMed ID: 7903944 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]